Interleukin-3 (IL-3) is a hematopoietic growth factor that supports the growth of early hematopoietic progenitors in vitro. In vivo administration of recombinant human interleukin-3 (rhIL-3) to normal primates results in a modest and delayed leukocytosis secondary to increases in neutrophils, basophils, and eosinophils. We postulated that the effects of rhIL-3 might be more pronounced in hematologically stressed primates, and therefore administered rhIL-3 to primates after intensive myelosuppressive therapy. Primates received either cyclophosphamide (CPM) at 60 mg/kg or 5-fluorouracil (5-FU) at 75 mg/kg i.v. on two consecutive days. Subsequently, rhIL-3 was administered intravenously or subcutaneously at 20 ,Ag/kg per d for 14 d. Compared to controls, all rhIL-3 treated primates experienced higher absolute neutrophil count (ANC) nadirs and dramatic decreases in the period of severe neutropenia (ANC < 500) after myelosuppressive therapy. RhIL-3 administration resulted in a significant basophilia and eosinophilia, which resolved after discontinuation of the drug. RhIL-3 did not enhance erythroid recovery. Platelet recovery was earlier in rhIL-3-treated animals. However, variations in the platelet recovery observed in control animals, precluded accurate estimation of this effect or its significance. Our results indicate that the administration of rhIL-3 following intensive myelosuppressive therapy dramatically enhances myeloid recovery and ablates the predicted period of prolonged severe neutropenia. (J. Clin. Invest. 1990Invest. . 85:1560Invest. -1565 interleukin-3 * cytokine * neutropenia* myelosuppression -eosinophilia. basophilia
Introduction
Interleukin-3 is a hematopoietic growth factor produced by activated T lymphocytes (1) . The recent cloning of the human IL-3 gene (2) , and subsequent production of purified recombi-1. Abbreviations used in this paper: ABC, absolute basophil count; AEC, absolute eosinophil count; ANC, absolute neutrophil count; CPM, cyclophosphamide; 5-FU, 5-fluorouracil; GM-CSF, granulocyte macrophage-colony stimulating factor; rhIL-3, recombinant human IL3. to define the effects of rhIL-3 on human bone marrow progenitor cells in vitro (3) (4) (5) (6) (7) (8) . In serum-free bone marrow culture, rhIL-3 supports the growth of early hematopoietic progenitors and synergistically acts with more restricted cytokines, such as erythropoietin or granulocyte colony-stimulating factor (G-CSF), in promoting the formation of erythroid, myeloid, mixed, and megakaryocytic colonies (3) (4) (5) . In bone marrow suspension cultures, IL-3 is a potent stimulator of eosinophil and basophil differentiation (6) (7) (8) .
The effects of rhIL-3 administration on hematopoiesis in normal healthy primates has also been recently described (9, 10) . rhIL-3 treatment resulted in a modest and delayed leukocytosis secondary to increases in neutrophils, basophils, and eosinophils. In addition, increases in corrected reticulocyte counts and variable increases in platelet counts were observed.
Although the hematopoietic effects of rhIL-3 in the intact primate are not as impressive as those of the more lineage-restricted cytokines such as G-CSF ( 11) or granulocyte-macrophage colony-stimulating factor (GM-CSF) (12), we postulated that the effects of rhIL-3 might be more pronounced in hematologically stressed animals. In this study, rhIL-3 was administered to cynomolgus primates after myelosuppressive chemotherapy. We report that rhIL-3 administered to cynomolgus primates post-myelosuppressive therapy ablates the predicted period of prolonged severe neutropenia. After myelosuppressive treatment (as described below), animals were treated aggressively with parenteral fluids, antibiotics, and irradiated blood products. Animals received whole blood transfusions from previously crossmatched donors for hemoglobin values < 9 g/dl.
Methods
Interleukin-3. Recombinant human interleukin-3 (Genetics Institute, Cambridge, MA) expressed in Escherichia coli was purified as previously described (9) . The purified rhIL-3 had a specific activity of 4.3 X 106 U/mg measured in the chronic myelogenous leukemia blast proliferation assay (2) the WBC nadirs of the rhIL-3 treated animal were 3.7 X 103/ mm3 and 3.6 X 103/mm3 following CPM cycles I and 2, respectively. The absolute neutrophil counts (ANC) of the rhIL-3 treated animal also remained greater than those of the control animals throughout the study ( Fig. 1 B) . After each CPM cycle, the control animals developed severe neutropenia, defined as an absolute neutropenia count below 0.5 X I03/ mm3. The ANC nadirs of both animals were 0.4 X 103/mm3 and 0.1 X 103/mm3 after CPM cycles 1 and 2, respectively ( Table I ). The duration of neutropenia in the control animals after CPM cycle 1 was 1 and 4 d, and following CPM cycle 2, 7 and 12 d (Table I ). The rhIL-3-treated animal did not develop severe neutropenia. The ANC remained > 1.0 X 103/mm3 after both cycles of CPM. Qualitatively, the WBC recovery post-CPM was different between the two groups. WBC recovery in control animals was composed primarily of neutrophils, lymphocytes and monocytes, in proportions comparable to those in normal cynomolgus peripheral blood (Fig. 2 A) . No significant eosinophilia or basophilia was observed. In contrast, the rhIL-3-treated animal developed a marked eosinophilia and basophilia (Fig. 2  B) . After each CPM cycle (Fig. 3) , absolute eosinophil counts (AEC) and absolute basophil counts (ABC) rose above the normal baseline values (0-505/mm3 and 0-213/mm3, respectively, based on peripheral white blood counts and differential obtained in 25 normal cynomolgus primates in our colony) by days 6-8 and reached a maximum on days 15-21. The AEC and ABC returned to normal baseline values by day 28 ofeach CPM cycle.
S-FU trial. 5-FU was administered to six primates. Subsequently, two of these primates (A and B) received a 14-d course of rhIL-3, and four control animals (C-F) received sham doses of normal saline over the same time period. rhIL-3-treated animals experienced a significant acceleration of both total white blood cell and neutrophil recovery after 5-FU compared with controls (Fig. 4) . Control animals developed a prolonged neutropenia, lasting 18-25 d, with ANC nadirs of 0.0-0.1 X 103/mm3 (Fig. 4 B, Table II ). In contrast, both rhIL-3-treated animals experienced only one day of severe neutropenia and ANC nadirs of0.4 X 103/mm3 (Fig. 4 B , Table II ). WBC recovery in rhIL-3-treated primates was associated with significant eosinophilia and basophilia, which was not observed in control animals. In primates A and B, an absolute eosinophilia developed between days 11-24, peaking on days 14 and 15 at 3.2 X 103/mm3 and 2.3 X 103/mm3, respectively (Fig. 5 A) . An absolute basophilia was observed in primates A and B on days 8-21, reaching maximal levels on (Fig. 5 B) . The incidence of rhGM-CSF stimulated CFU-GM per 1 X 105 bone marrow mononuclear cells following 5-FU with or without rhIL-3 treatment is depicted in two representative primates (Fig. 6) . Animals receiving rhIL-3 experienced a more rapid recovery of CFU-GM, achieving baseline values by day 14 compared to day 21 in controls. Similar results were obtained with in vitro stimulation of CFU-GM with rhG-CSF and rhIL-3.
We observed no obvious differences in erythroid recovery post-5-FU in rhIL-3-treated versus control animals, as measured by recovery of corrected reticulocyte counts and the red cell transfusion requirements of the animals.
5-FU administration, unlike CPM, resulted in a significant depression of platelet counts below baseline levels (Fig. 7) . Among the four control animals platelet counts fell from 273 to 553 X 103/mm3 on day -2 to nadir counts of 96-150 X 103/mm3 between days 14 and 19 (Table II) . Platelet counts remained depressed greater than 30 days in two control animals (C, D). However, two controls (E, F) experienced abrupt increases in platelet counts beginning on days 17 and 15, reaching maximum levels of 668 and 808 X 103/mm3, respectively. Nadir platelet counts in the IL-3-treated primates (A, B), of 117 and 368 X 103/mm3 occurred on days 11 and 12, respectively (Table II) . Abrupt platelet count recovery occurred in both animals beginning on days 11 RhIL-3 toxicity. All rhIL-3-treated primates developed localized facial and extremity swelling 8 to 11 days after the initiation of rhIL-3 treatment. The swelling was non-pitting and not associated with weight gain. Concurrently, a pruritic rash developed consisting of 1-2 cm yellow to pink indurated papules. Biopsy of the affected dermis revealed perivascular infiltration of neutrophils and eosinophils. No life-threatening allergic symptomatology was noted. The rash and swelling resolved within one week of rhIL-3 discontinuation. All rhIL-3 treated primates also developed mild splenomegaly without hepatomegaly. No hepatic or renal toxicity was observed.
Discussion
To examine the effect of rhIL-3 on hematopoiesis in hematologically stressed primates, we administered two different and diverse cytotoxic agents: cyclophosphamide, an alkylating agent that is cycle nonspecific and relatively platelet sparing; and 5-fluorouracil, an antimetabolite, which is cycle specific and at doses employed in this study extremely myelosuppressive. In mice, this dose of 5-FU has been shown to spare only those primitive marrow progenitors with high proliferative potential (13, 14) . We attempted to administer two cycles of each chemotherapeutic agent in order to mimic pulse repetitive cytotoxic therapy as it is commonly used in human trials, however the animals receiving 5-FU were only able to tolerate one cycle of therapy due to severe gastrointestinal toxicity. The administration of rhIL-3 following both cytotoxic agents clearly resulted in a marked enhancement of myeloid recovery. In both experiments, rhIL-3-treated primates compared to controls experienced higher absolute neutrophil count nadirs and an ablation or a significant decrease in the period of severe neutropenia following myelosuppression. In addition to changes in the peripheral counts, we also observed evidence of earlier recovery of myeloid progenitors in sequential clonal assays of bone marrow in rhIL-3-treated primates compared to controls following 5-FU treatment.
In the CPM experiment, rhIL-3 administration after two consecutive cycles of high-dose alkylator therapy did not lead to demonstrable enhanced depletion of marrow progenitors capable of reconstituting hematopoiesis or significantly enhance the sensitivity of early hematopoietic progenitors to subsequent cytotoxic therapy, since the hematopoietic response seen after the second cycle of CPM was equivalent or even perhaps better, than that observed after the first CPM cycle.
In in vitro studies, rhIL-3 when combined with erythropoietin exhibits substantial burst-promoting activity (15) . However, we could not demonstrate a stimulatory effect of rhIL-3 on the erythroid lineage in the 5-FU experiments. It is possible that the necessary transfusion of whole blood to the primates blunted an erythroid response. Furthermore, our measures of red blood cell production, which included only corrected reticulocyte counts and transfusion requirements, may not have been sufficiently sensitive to discern alterations in erythroid precursor recovery in animals undergoing daily blood samplings and experiencing gastrointestinal blood losses, thereby requiring varying amounts of transfusion support.
In vitro serum-free marrow culture studies have also demonstrated that rhIL-3 is a megakaryocyte colony stimulating factor (16, 17) . In this study, the effect of rhIL-3 on megakaryopoiesis could only be assessed in the 5-FU experiments. In the 5-FU trial, the four control animals exhibited two very different patterns of platelet recovery. Primates C and D displayed very prolonged delays in platelet recovery, while primates E and F experienced abrupt elevations in platelet counts to twice baseline levels on days 15 and 17. This latter pattern of recovery was exhibited by the rhIL-3 treated primates. However, it occurred earlier, on days 11 and 14, suggesting that IL-3 may also stimulate more prompt recovery of megakaryopoiesis in vivo. Additional experiments are in progress to accurately assess differences in platelet recovery times and their significance.
In bone marrow suspension culture systems, rhIL-3 induces the growth of basophils and the production of intracellular histamine (18) . The administration of rhIL-3 to normal rhesus primates results in dramatic increases in blood eosinophils and basophils and a dose-dependent increase in intracellular histamine and to a less extent plasma histamine (10) . Whether rhIL-3 induces blood basophils to release intracellular histamine is currently debated in the literature. Valent et al. (18) have reported that rhIL-3 is not a histamine releasing factor, while Haak-Frendscho et al. (19) have reported the converse. In this study, we observed significant basophilia and eosinophilia in all rhIL-3-treated primates. This basophil increase if also associated with an increase in plasma histamine, would explain the side effects observed in the rhIL-3-treated animals. All animals developed localized swelling and a pruritic rash concomitant with the increase in basophil numbers, which completely resolved as basophil numbers returned to normal levels. Biopsy of the rash was consistent with an urticarial lesion. It is important to note, however, that in this study and in the previously reported in vivo rhIL-3 primate trials (9, 10), animals with abnormally high basophil counts have not developed any serious or life-threatening allergic symptoms. These results strongly encourage the testing of rhIL-3 in human clinical trials. rhIL-3, like G-CSF and GM-CSF, clearly has stimulating effects on myeloid recovery postcytotoxic chemotherapy. It is also possible that IL-3 will be more effective than G-CSF and GM-CSF in stimulating hematopoietic recovery in patients treated with myeloablative dose of agents such as 5-FU, which effect early marrow progenitors. Further studies are required to accurately assess the effects of rhIL-3 on red cell and platelet recovery. However, our results suggest that IL-3 may also stimulate earlier recovery of megakaryopoiesis. To better define these issues, we are currently evaluating the effects of rhIL-3 on hematopoietic recovery following ablative doses of total body irradiation and autologous transplants of deescalating doses of marrow progenitors.
